Your browser version may not work well with NCBI's Web applications. More information here...
1: Trends Endocrinol Metab. 2004 Mar;15(2):49-50.Links

Does bone resorption inhibition affect the anabolic response to parathyroid hormone?

Martin TJ.

University of Melbourne, St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia. thomasjm@unimelb.edu.au

One of the questions arising from the use of parathyroid hormone (PTH) as an anabolic agent is whether preventing bone loss with inhibitors of bone resorption might result in a greater amount of bone in response to PTH. Two recent independent reports indicate that the anabolic effect of PTH in osteoporotic women appears to be significantly reduced when alendronate is administered in combination with PTH in studies using biochemical markers, quantitative computed tomography and bone mineral density (BMD) measurements. The very different mechanisms of the two treatments reduces the impact of the BMD data, but if the overall conclusion is correct, an effect of PTH on resorption might be necessary for the anabolic effect to follow.

PMID: 15080150 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Alendronate (Fosamax® , Fosamax Plus D® )

    Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change of life,' end of menstrual periods) and to treat...

  • Source: AHFS Consumer Medication Information